Skip to main content
European Commission logo print header

Female Reproductive toxicity of EDCs: a human evidence-based screening and Identification Approach

Project description

Endocrine-disrupting chemicals and female reproductive health assessment

The EU-funded FREIA project aims to develop test methods to identify human-made endocrine-disrupting chemicals (EDCs) and their effects on the female reproductive system. Current safety tests often overlook the impact of EDCs, meaning that women's reproductive health is at risk globally. The FREIA consortium has developed human tissue models representing the entire life cycle, from fetal ovarian and adrenal tissues to mature ovarian follicles, to identify biomarkers of EDC exposure. Research integrates the data from in vitro studies with primary human tissues, human exposure data from fetal and follicular fluid samples, and in vitro and in vivo research findings. The FREIA project is well-positioned to accumulate novel information on EDC-related reproductive health risks to improve women's reproductive health around the world.

Objective

The FREIA consortium aims to close gaps in scientific knowledge on the mechanisms by which EDCs can affect female reproduction during specific life stages and will provide test methods to address this. The FREIA consortium has human tissue models that span the entire life cycle from fetal ovarian and adrenal tissues to child and mature ovarian follicles, that will be used identify human relevant biomarkers of EDC exposure. We will measure chemical exposures in follicular fluids and molecular profiles in granulosa cells from two IVF cohorts, and link these to fertility outcomes and patient journal information, including life-style factors and workplace. We will perform in vivo rodent studies to capture susceptible windows of exposure and identify novel endpoints for female reproductive toxicity that may be implemented in OECD test guidelines. We will provide in vitro test methods, according to OECD guidelines, for molecular and cellular events that have been implicated in female reproductive toxicity. These include ER-beta activity, GPER activity, ovarian-specific steroidogenesis, oocyte maturation and competency and hypothalamic pulsatile GnRH secretion. We will also develop QSAR models to predict interaction with aromatase and PPAR-gamma. By integrating our data from in vitro studies with primary human tissues, human exposure data from fetal and follicular fluid samples and our in vitro and in vivo research findings, the outcomes of FREIA are directly applicable to the human situation. AOPs will be developed that will form the basis for a test strategy to assess female reproductive toxicity upon exposure to EDCs, in a regulatory context. Furthermore, by expanding our scientific knowledge, the FREIA project will provide better information on EDC-related female reproductive health effects that will be used to improve reproductive health for women around the world.

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2018-Single-Stage-RTD

æ

Coordinator

STICHTING VU
Net EU contribution
€ 1 529 108,75
Address
De boelelaan 1105
1081 HV Amsterdam
Netherlands

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Links
Other funding
€ 0,00

Participants (10)